Latest Healthcare News

Cambium Bio has secured ethics approvals in Australia and the US to initiate pivotal Phase 3 trials of Elate Ocular, targeting moderate to severe dry eye disease, with patient dosing expected in October 2025.

Actinogen Medical has enrolled its 100th participant in the XanaMIA phase 2b/3 Alzheimer’s trial, setting the stage for a critical interim analysis in January 2026 and final results by year-end.

ECS Botanics has launched the globally acclaimed Terphogz™ cannabis strains, including The Original Z™, into the Australian medicinal market, marking a strategic expansion of its premium product portfolio.

Vitasora Health has expanded its partnership with The Physician Alliance Corporation from a pilot to a multi-year value-based care contract covering up to 15,000 Medicare patients, unlocking significant new revenue streams tied to patient outcomes.

Dimerix Limited has received a significant milestone payment from its Japanese partner FUSO Pharmaceutical, marking progress in the Phase 3 clinical trial of DMX-200 for kidney disease. This payment underscores the growing momentum behind Dimerix’s global licensing strategy.

BlinkLab has secured US Institutional Review Board approval to proceed with the main phase of its FDA 510(k) trial for an AI-powered autism diagnostic tool, marking a key step toward regulatory clearance.

Memphasys Limited has submitted its CE Mark application for the Felix™ sperm separation device, targeting regulatory clearance within 6-12 months to unlock the lucrative European IVF market and accelerate approvals in other key regions.

Proteomics International has achieved a major milestone with the first worldwide patent granted in Japan for its PromarkerEndo blood test, designed to diagnose endometriosis early and accurately.

Microba Life Sciences invites eligible shareholders to participate in a $2 million Share Purchase Plan at $0.09 per share, matching recent institutional pricing and including free attaching options. The capital raise aims to accelerate clinical adoption and push the company towards regional break-even.

Microba Life Sciences has announced a $14.5 million capital raising, including a $2 million fully underwritten Securities Purchase Plan (SPP) and a $12.5 million Placement, aimed at fast-tracking commercialisation of its microbiome diagnostic tests in Australia and the UK.

Epsilon Healthcare and its subsidiaries have officially exited voluntary administration and Deeds of Company Arrangement, marking a pivotal recovery milestone supported by significant personal commitments from the new board. The company now shifts focus to strategic growth and rebuilding trust.

Oceania Holdings Limited showcased robust operational progress and a strategic pivot towards portfolio modernization at its 2025 Annual Meeting, while announcing a new cost savings program and withholding its final dividend for FY25.